Clinical trial · Interventional
Impact of the Use of Nandrolone on the Treatment of Malnutrition Induced by Cancer
NCT03263520CI-TRIAL-00037290completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Compare the use of nandrolone associated with corticosteroid for the treatment of cancer-induced malnutrition to treatment with corticosteroids alone in patients with tumors in the high gastro-intestinal tract, liver, pancreas and bile ducts in palliative treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cachexia; Cancer | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dexamethasone | Drug | Dexamethasone | ALIAS |
| Nandrolone Decanoate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Group 1: nandrolone and corticosteroid
- description
- the patient will receive an application of anabolic nandrolone decanoate at a dose of 50 mg (males) and 25 mg (females), intra-muscular form, in the first and fifteenth days. In addition to the anabolic steroid, the patient will use corticosteroids (dexamethasone) at home at a dose of 4 mg daily by mouth on the morning for both sexes for 30 days.
- interventionNames
- Drug: Nandrolone Decanoate
- type
- ACTIVE_COMPARATOR
- label
- Group 2: corticosteroid
- description
- Patient will take corticosteroids ( 4 mg of dexamethasone) per oral, QD at morning for 30 days
- interventionNames
- Drug: Dexamethasone
Primary outcomes (3)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Cancer patients above 18 years old. * Patients with tumors in the high gastro-intestinal, hepatobiliary and pancreatic tracts in palliation. * Patients able to undergo BIA. * Malnourished patients as per the subjective global assessment produced by the patient (ASG-PPP) and whose score is greater than nine. * Patients who agree to participate in the study. Exclusion Criteria: * Patients with malignant tumors of other metachronous or synchronous location except nonmelanoma skin tumor * Patients with chronic renal failure. * Patients on diuretics, recent or chronic. * Patients on appetite stimulants and anabolic agents. * Patients using pacemakers, which can interfere with the results of BIA
References
Publications (0)
Data not yet available
No reference posted for this study.